Strategic Global Pact: Dr Reddy's and Immutep Join Forces on Cancer Drug

Dr Reddy's Laboratories and Immutep Ltd have entered a strategic licensing agreement for the cancer therapy Eftilagimod Alfa (Efti). This partnership excludes North America, Europe, Japan, and Greater China but promises significant milestone payments, global manufacturing rights, and royalties. Dr Reddy's will facilitate Efti's growth in emerging markets.

Dr Reddy's Laboratories and Immutep Ltd have announced a strategic collaboration focusing on the development and commercialization of their pioneering cancer immunotherapy, Eftilagimod Alfa (Efti). This groundbreaking agreement covers all countries except North America, Europe, Japan, and Greater China.

Efti, known for its potential in treating non-small cell lung cancer, among others, will see its global reach expanded through this venture. The collaboration allows Immutep to retain manufacturing rights, while Dr Reddy's will utilize its market expertise to enhance Efti's presence across various markets.

Immutep will receive an initial USD 20 million, with additional potential earnings up to USD 349.5 million, plus royalties. Both companies foresee a promising future for Efti, leveraging Dr Reddy's extensive network to deliver innovative solutions to cancer patients worldwide.

(With inputs from agencies.)